3 Penny Stocks With At Least $50M Market Cap

In This Article:

The U.S. stock market has recently seen a rebound, buoyed by an encouraging Consumer Price Index report that suggests potential adjustments in Federal Reserve policies. For investors seeking opportunities beyond the well-known giants, penny stocks—typically smaller or newer companies—can present intriguing possibilities despite their somewhat outdated label. This article explores three penny stocks that showcase financial strength and potential for growth, offering investors a chance to uncover hidden value in robust companies.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.82055

$5.93M

★★★★★★

Sensus Healthcare (NasdaqCM:SRTS)

$4.45

$71.75M

★★★★★★

Safe Bulkers (NYSE:SB)

$3.71

$384.78M

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$135.96M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.36

$70.37M

★★★★★★

Tuya (NYSE:TUYA)

$3.92

$2.26B

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8627

$78.36M

★★★★★☆

PHX Minerals (NYSE:PHX)

$3.77

$136.8M

★★★★★☆

TETRA Technologies (NYSE:TTI)

$3.27

$434.25M

★★★★☆☆

Click here to see the full list of 760 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Applied Therapeutics

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel product candidates for high unmet medical needs in the United States, with a market cap of approximately $59.60 million.

Operations: The company's revenue segment is solely focused on discovering and developing its product candidates, which generated -$0.21 million.

Market Cap: $59.6M

Applied Therapeutics, Inc. faces challenges as a pre-revenue biopharmaceutical firm with a market cap of US$59.60 million, recently receiving a Nasdaq delisting notice due to its stock trading below US$1 for 30 days. Despite having over US$104 million in short-term assets covering liabilities and no debt, the company struggles with high volatility and an unprofitable status. Recent executive changes aim to stabilize operations, yet legal issues regarding clinical practices remain unresolved. While revenue growth is forecasted at over 50% annually, significant hurdles persist in achieving profitability within three years amidst ongoing compliance efforts.